ABL Bio (XKRX:298380) Total Stockholders Equity : ₩63,808 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is ABL Bio Total Stockholders Equity?

ABL Bio's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ₩63,808 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. ABL Bio's Book Value per Share for the quarter that ended in Mar. 2024 was ₩1,332.31. The ratio of a company's debt over equity can be used to measure how leveraged this company is. ABL Bio's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.68.

ABL Bio Total Stockholders Equity Historical Data

The historical data trend for ABL Bio's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ABL Bio Total Stockholders Equity Chart

ABL Bio Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

132,008.20

90,664.63

55,952.94

69,513.28

74,079.11

ABL Bio Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial															95,905.01	87,612.22	85,672.79	74,079.11	63,807.83

ABL Bio (XKRX:298380) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

ABL Bio's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(63807.832	-	0)	/	47.8925
	=	1,332.31

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

ABL Bio's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(531.253	+	43070.554)	/	63807.832
	=	0.68

ABL Bio Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of ABL Bio's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

ABL Bio (XKRX:298380) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ABL Bio Inc (XKRX:298380) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

2nd Floor, 16 Daewangpangyo-Ro 712, Beon-Gil, Bundang-Gu, Gyeonggi-do, Seongnam-si, KOR, 13488

Website

https://www.ablbio.com

ABL Bio Inc is a Korean biotech research company. The company is engaged in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline products include ABL001 an Bispecific Antibody, ABL201-205 an Antibody Drug Conjugate, T cell engager, Dual Immune Cell Targeting BsAb an Immuno-Oncology, ABL301 an BBB-Penetrating Bispecific Antibody.

ABL Bio (XKRX:298380) Headlines

No Headlines